NCT04910152终止1 期
A Single Arm, Open Label, Phase 1b/2 Study of Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Hannah Choe, MD1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2022年4月19日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Maximum Tolerated Dose (MTD)
研究概览
简要总结
This phase Ib/II trial studies the side effects of PLX51107 in treating steroid-refractory acute graft versus host disease (GVHD). PLX51107 is a novel, potent non-benzodiazepine structured small molecule BET inhibitor with a unique binding mode selective for BRD4 inhibition and a more tolerable side effect profile. PLX51107 may work better in treating steroid-refractory acute GVHD.
详细描述
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability of BRD4 inhibitor PLX51107 (PLX51107) as a single agent for allogeneic transplant recipients with steroid-refractory acute graft versus host disease (GVHD).
II. To assess the pharmacokinetic (PK) and pharmacodynamic (PD) of orally administered PLX51107 in steroid-refractory acute GVHD patients.
SECONDARY OBJECTIVE:
I. To evaluate the preliminary efficacy of PLX51107 in steroid-refractory acute GVHD patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >= 18 years at the time of signing informed consent
- •Steroid-refractory acute GVHD as defined as progression of acute (a)GvHD within 3-5 days of therapy onset with >= 2 mg/kg/day of prednisone equivalent OR failure to improve within 5-7 days of treatment initiation with > 1-2 mg/kg/day of prednisone equivalent OR incomplete response after more than 28 days of immunosuppressive treatment including steroids
- •Recipients of ablative and reduced-intensity conditioning regimens
- •Recipients of human leukocyte antigen (HLA)-matched related and unrelated, 1-allele mismatched, haploidentical, or umbilical cord blood donor grafts
- •Prior lines of therapy for treatment of steroid-refractory acute GVHD are allowed. However, exposure to investigational therapies for the treatment of GVHD must be > 14 days or 5 half-lives (whichever is shorter) of first administration of study drug. For patients treated with ruxolitinib for the treatment of acute GVHD, ruxolitinib must be discontinued by at least one day prior to initiation of PLX51107
- •Eastern Cooperative Oncology Group (ECOG) performance status =< 3
- •Absolute neutrophil count >= 1.0 x 10^9/L for 3 consecutive days). Use of growth factor support is allowed
- •Platelet count >= 50 x 10^9/L without transfusion support for 2 consecutive days
- •Women of child-bearing potential must have a negative serum pregnancy test at Screening and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for >= 1 year
- •Fertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug
排除标准
- •Prior exposure to a bromodomain inhibitor
- •Evidence of chronic GVHD
- •Evidence of active relapse of disease
- •Exposure to other investigational or anti-cancer therapies (not for GVHD) within 28 days or 5 half-lives (whichever is shorter) of first administration of study drug
- •Active, uncontrolled bacterial, fungal, or viral infection
- •Known or suspected allergy to the study drug
- •Clinically significant cardiac disease, defined as:
- •Clinically significant cardiac arrhythmias, including bradyarrhythmia, and/or a need for anti-arrhythmic therapy (excluding beta blockers or digoxin). Individuals with controlled atrial fibrillation are not excluded
- •Fridericia-corrected QT interval (QTcF) >= 450 ms (male) or >= 470 ms (female) at screening
- •History of clinically significant cardiac disease or congestive heart failure greater than New York Heart Association Class II. Subjects must not have unstable angina (angina symptoms at rest) or experienced either new-onset angina within the last 3 months or myocardial infarction (MI) within the last 6 months unless it was due to the underlying disease and there has been appropriate revascularization. Individuals with ambiguous troponin levels that are not diagnostic of an MI should be discussed with the principal investigator (PI) prior to enrollment
- •Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within the 6 months before start of study medication (except for catheter-related venous thrombosis
- •Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption
- •Active thrombotic microangiopathy (TMA)
- •Women who are either pregnant or breast feeding
- •Measured or calculated (Cockcroft-Gault formula) creatinine clearance (CrCl) < 45 mL/min
- •Prothrombin time or international normalized ratio > 1.5 x upper limit of normal (ULN)
- •Activated partial thromboplastin time > 1.5 x ULN
- •Requiring mechanical ventilation or vasopressor support
- •Subject is participating in any other therapeutic clinical study (observational or registry studies are allowed)
研究组 & 干预措施
Treatment for aGVHD (BRD4 inhibitor PLX51107)
Experimental
Patients receive BRD4 inhibitor PLX51107 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: BRD4 Inhibitor PLX51107 (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD)
时间窗: Up to 28 days
Incidence of Adverse Events Grade 3 and 4
时间窗: Up to 6 months
Adverse events by grade will be summarized. The occurrence of grade 3+ adverse events according to Common Terminology Criteria for Adverse Events will be summarized as well. Adverse events will initially be reviewed regardless of attribution, but also according to whether adverse events are possibly, probably, or definitely related to treatment.
次要结局
- Complete Response (CR)(At day 28)
- Overall Response Rate(At day 28)
- Non-relapse Mortality (NRM)(From the date of starting PLX51107 to date of death with the competing risk as death due to disease, assessed at 6 months)
研究者
Hannah Choe, MD
Principal Investigator
Ohio State University Comprehensive Cancer Center
研究点 (1)
Loading locations...
相似试验
已完成
1 期
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative NeoplasmAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT04022785M.D. Anderson Cancer Center43
已完成
2 期
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With DocetaxelHormone-refractory Prostate CancerNCT00082134Genzyme, a Sanofi Company40
已完成
1 期
Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CFCystic FibrosisNCT01840735Gilead Sciences8
已完成
1 期
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaAdult Anaplastic (Malignant) MeningiomaAdult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Brain Stem GliomaAdult Choroid Plexus NeoplasmAdult CraniopharyngiomaAdult Diffuse AstrocytomaAdult EpendymoblastomaAdult EpendymomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Grade I MeningiomaAdult Grade II MeningiomaAdult MedulloblastomaAdult Mixed GliomaAdult Myxopapillary EpendymomaAdult OligodendrogliomaAdult Papillary MeningiomaAdult Pilocytic AstrocytomaAdult Pineal Gland AstrocytomaAdult PineoblastomaAdult PineocytomaAdult Primary Melanocytic Lesion of MeningesAdult Subependymal Giant Cell AstrocytomaAdult SubependymomaAdult Supratentorial Primitive Neuroectodermal TumorMalignant Adult Intracranial HemangiopericytomaAcoustic SchwannomaNCT01119599National Cancer Institute (NCI)22
已完成
1 期
A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic MelanomaMalignant MelanomaNCT01107418Hoffmann-La Roche52